Follow The Filings

DHR Danaher

Health Care, filed as DANAHER CORPORATION (COM), Equity As of 2026 Q3 among managers we track Quote on Google Finance, opens in a new tab

Bought by 9 managers in 2026 Q2, sold by 2

  • 3 Owners
  • #23
  • Max 0.1%
  • Master 0.10%
  • $790K

Who owns this now

Largest portfolio weights among holders, up to 0.1% (Torray Investment Partners). Not free-float ownership.

  1. Torray Investment Partners 0.05%
  2. David Katz 0.03%

Who owns DHR

Sorted by value, long equity only, as of 2026 Q3.

History
Torray Investment Partners 0.05% Hold 1,871 $415K History
David Katz, Matrix Asset Advisors 0.03% Hold 1,681 $372K History
Kentucky Trust Co., Kentucky Trust <0.01% Hold 13 $3K History

3 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by DHR's executives, directors and 10% owners in the last 12 months, from their Form 4s

All DHR insider trades
  • None no insider bought on the open market
  • $267M sold by 9 insiders outside a trading plan
  • None no planned (10b5-1) sales
  1. Christopher Bouda VP, Chief Accounting Officer
    Sale
    $1.8M 7,598 shares at $234.56 46% of stake
    Traded Oct 28 Filed Oct 29
    ↗
  2. Matthew McGrew Executive Vice President
    Sale
    $7M 29,754 shares at $235.74 70% of stake
    Traded Oct 28 Filed Oct 29
    ↗
  3. Rainer Blair CEO
    Sale
    $12.7M 58,255 shares at $218.63 100% of stake
    Traded Aug 21 Filed Aug 24
    ↗
  4. Alan G Spoon Director
    Sale
    $237K 1,358 shares at $174.67 1.1% of stake
    Traded May 1 Filed May 4
    ↗
  5. Gregory M Milosevich Executive Vice President
    Sale
    $275K 1,320 shares at $208.01 21% of stake
    Traded Feb 19 Filed Feb 20
    ↗
  6. Mitchell P Rales Chairman of Exec. Committee
    Sale
    $9.4M 40,625 shares at $230.38 4.6% of stake
    Traded Nov 25, 2025 Filed Nov 26, 2025
    ↗
  7. Teri List Director
    Sale
    $747K 3,298 shares at $226.50 14% of stake
    Traded Nov 18, 2025 Filed Nov 19, 2025
    ↗
  8. Mitchell P Rales Chairman of Exec. Committee
    Sale
    $95.6M 437,000 shares at $218.69 44% of stake
    Traded Nov 12, 2025 Filed Nov 13, 2025
    ↗
  9. Matthew McGrew CFO
    Sale
    $3.5M 16,172 shares at $214.62 45% of stake
    Traded Nov 11, 2025 Filed Nov 13, 2025
    ↗
  10. Brian W Ellis Senior Vice President - GC
    Sale
    $4.8M 21,776 shares at $219.23 60% of stake
    Traded Nov 12, 2025 Filed Nov 13, 2025
    ↗
  11. Georgeann Couchara SVP, Human Resources
    Sale
    $1.1M 5,174 shares at $210.42 66% of stake
    Traded Nov 10, 2025 Filed Nov 12, 2025
    ↗
  12. Mitchell P Rales Chairman of Exec. Committee
    Sale
    $130M 600,000 shares at $216.06 38% of stake
    Traded Oct 31, 2025 Filed Nov 4, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 33 stock grants, 25 share withholdings for taxes, 12 option exercises, 2 sales back to the company, and 2 gifts.

Congress

17 members of Congress traded DHR in the last three years: 10 buys and 19 sales. 14 members listed it in 2025 annual reports.

All Congress trades
  1. Kevin Hern R-OK-1Joint Partial sale $1K–$15K Sep 2 filed Sep 25
  2. Kevin Hern R-OK-1Joint Sell $15K–$50K Aug 31 filed Sep 25
  3. Alan Armstrong R-OK Buy $1K–$15K Mar 27 filed Jul 21
  4. Julie Johnson D-TX-32Joint Sell $1K–$15K Dec 18, 2025 filed Jan 15
  5. Julia Letlow R-LA-5 Buy $1K–$15K Apr 28, 2025 filed Jan 13
  6. Julie Johnson D-TX-32Joint Partial sale $1K–$15K Nov 13, 2025 filed Dec 11, 2025

SEC filings

Recent issuer filings from EDGAR, 7 shown.

Filed Form Detail Links
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.02,8.01 Filing Doc
8-K 5.02,7.01,8.01,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 2.03,8.01 Filing Doc

Source: SEC EDGAR submissions, updated about 15 hours ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $23.89B $23.88B $24.57B
Gross profit $14.03B $14.21B $14.52B
Gross margin * 58.7% 59.5% 59.1%
Net income $4.76B $3.9B $3.61B
Net margin * 19.9% 16.3% 14.7%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $13.94B $9.5B $12.76B
Total non-current assets * $70.55B $68.04B $70.71B
Total assets $84.49B $77.54B $83.46B
Total current liabilities $8.27B $6.8B $6.81B
Total equity $53.49B $49.54B $52.53B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $7.16B $6.69B $6.42B
Cash from investing -$7.08B -$1.98B -$1.2B
Cash from financing -$0.273B -$8.38B -$2.96B
Net change in cash -$0.131B -$3.79B $2.54B

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.